



Corporate Presentation

Nasdaq: PLXP

Forward-Looking Statements

This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements include, but are not limited to information or assumptions about expenses, capital and other expenditures, financing plans, capital structure, cash flow, liquidity, managements' plans, goals and objectives for future operations and growth. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases beyond our control and which could cause actual performance or results to differ materially from those expressed in or suggested by forward-looking statements.

Important factors that could cause such differences include, but are not limited to (i) our ability to bring both Vazalore™ 81 mg and Vazalore 325 mg to market-readiness; (ii) our ability to maintain regulatory approval of Vazalore 325 mg or obtain and maintain regulatory approval of Vazalore 81 mg and any future product candidates; (iii) the benefits of the use of Vazalore 325 mg and Vazalore 81 mg; (iv) our ability to successfully commercialize our Vazalore products, or any future product candidates; (v) the rate and degree of market acceptance of our Vazalore products or any future product candidates; (vi) our ability to scale up manufacturing of our Vazalore products to commercial scale; (vii) our ability to successfully build a specialty sales force and commercial infrastructure or collaborate with a firm that has these capabilities; (viii) our ability to compete with companies currently producing GI-safer technologies for NSAIDs and other analgesics; (ix) our reliance on third parties to conduct our clinical studies; (x) our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us; (xi) our ability to retain and recruit key personnel, including development of a sales and marketing function; and (xii) our ability to obtain and maintain intellectual property protection for our Vazalore products or any future product candidates.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Our Mission

PLx Pharma is focused on developing & commercializing next-generation oral NSAIDs and other drugs that leverage our proprietary PLxGuard™ technology to achieve greater efficacy and improved safety. We are driven to transform the standard of care for high-risk cardiovascular patients.

Novel Drug Delivery Technology

Achieves greater efficacy with improved acute GI safety

Mechanism of action enables strong patent life and is applicable to a variety of APIs

Lead Product: Vazalore™



Clinically proven to overcome the limitations of enteric-coated aspirin with faster-acting, more reliable and predictable efficacy and improved acute GI Safety




Late-stage product opportunity: Over-the-Counter (OTC), next generation aspirin with a 325mg dose (FDA approved) and an 81mg dose both expected to launch by mid-2020



Addresses a \$12+ billion high-risk cardiovascular patient market



•World-renowned key opinion leader advisory board (including Chairman, Dr. Deepak L. Bhatt and Dr. Gabrielle Steg) that understand and advocate for our innovative solution as a new standard of care



Significant physician interest in Vazalore – WSM¹ research positioned Vazalore in the top 5% of all health care professional recommended or prescribed products tested in the past 20+ years

1- Weinman Schnee Morais Inc.

VAZALORETM

Aspirin Capsules, 325 mg
Pain Reliever/Fever Reducer (**NSAID**)


325mg

**FIRST LIQUID-
FILLED ASPIRIN
CAPSULES**



Current Aspirin Landscape

34% of U.S. Population Falls in Categories for which Aspirin Would be Recommended ¹



GI complications from NSAIDS limit compliance



50+ million people who could benefit from aspirin use are left vulnerable to cardiovascular events

1. U.S. Census Bureau estimate, September 2014

Current Aspirin Landscape

Widespread usage

- Aspirin is one of the most widely-used drugs in the world

Global standard of care

- Foundational drug used to treat and prevent the leading cause of death, cardiovascular disease – Highest recommendation for secondary prevention treatment guidelines

Enteric-coated aspirin dominates the market

- >90% of U.S. sales, due to the perception that it has equal efficacy (decrease in platelet aggregation) and better safety (GI) than regular aspirin – neither of which is correct

Treatment/Compliance limitations

- **EFFICACY:** ~25% of EC aspirin treated patients have minimal absorption of aspirin
- **SAFETY:** Gastrointestinal (GI) upset / intolerability could limit patient compliance

Published Studies Support Aspirin – Not Enteric-Coated Aspirin

More than 200 studies support aspirin benefits

EVERY important clinical study supporting cardiovascular benefit of aspirin was conducted using immediate release (regular) aspirin – not (enteric-coated).¹


JAMA 2014: Study in >14,000 high-risk primary prevention subjects comparing 100mg enteric-coated aspirin vs. no aspirin stopped after 5 years, because they found no benefit for enteric-coated aspirin.²

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988; 2: 349–60
2. Ikeda Y *et al*, Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors A Randomized Clinical Trial. *JAMA*. 2014;312(23):2510-2520. doi:10.1001/jama.2014.15690



Why Can Enteric-Coated Aspirin Still Cause Ulcers?

Unidirectional Protection

- 1 Stomach**
EC aspirin tablet remains intact in stomach (pH 3)
- 2 Duodenum (small intestine)**
EC aspirin disintegrates in duodenum (pH 5.5)
- 3 Result**
Released aspirin can now freely reflux back into the stomach and induce surface injury



Vazalore's Novel Delivery System & Mechanism of Action



1 Liquid aspirin – lipid matrix does not permit release of aspirin in the stomach


2 In the duodenum, digestive agents emulsify the lipid matrix for absorption

3 With normal digestion, it refluxes back and forth between the duodenum & stomach

4 In the duodenum, the aspirin and the lipid come apart for further absorption

Vazalore selectively releases aspirin in the duodenum, which enables better and more reliable antiplatelet efficacy

Vazalore Clinically Demonstrates Better Absorption & Antiplatelet Efficacy than Enteric-Coated (EC) Aspirin



- Single dose pharmacokinetics and thromboxane depletion in non-insulin dependent diabetics
- Two independent studies in 92 subjects
 - PL-ASA-004 published in the *Journal of American College of Cardiology*¹
 - PL-ASA-006 study manuscript in preparation

Vazalore has fast, predictable and reliable absorption and antiplatelet activity

1. Bhatt et al/ Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus, JACC, Jan 2017, 23269; DOI: 10.1016/j.jacc.2016.11.050

Vazalore Has Better Acute GI Safety

Aspirin's Gastric Injury


- Aspirin induces corrosive damage by direct contact with the gastric surface - manifested as ulceration and bleeding
- Endoscopy demonstrates EC aspirin is not GI safer, with no difference in ulcer risk compared to regular aspirin ¹

Vazalore Solution

- Vazalore's lipid matrix release is based on pH, presence of bile, and enzymatic digestion
- Resulting in predictable and complete aspirin release in the small intestine
- Fewer gastric erosions and acute ulcers

1. Kelley DJ, et al. *Lancet*. 1996;348;1413-1416
2. American Journal of Gastroenterology, 2010 and unpublished PLx studies

65% Fewer Acute Gastric Ulcers



Seven day endoscopy endpoints combined from two PLx clinical studies (PL-ASA-002 and PL-ASA-005) endoscopy trials with Vazalore 325 mg vs. regular 325 mg aspirin taken daily, in **441 subjects** with an age-associated risk for cardiovascular disease, demonstrated a minimum of **65% reduction** in risk for gastric ulcers ²

Vazalore has Better Acute GI Safety than Regular Aspirin

Vazalore: Unleashing Aspirin's Full Potential

Differentiated Marketing Claims

- **EFFICACY: 3-5 times greater chance of complete antiplatelet effect than EC aspirin**
 - In head-to-head clinical trials with EC aspirin, Vazalore 325 mg provided faster acting, more reliable, predictable and sustainable antiplatelet efficacy than EC aspirin
- **SAFETY: 65% lower risk of acute gastric ulceration than regular aspirin**
 - EC aspirin is not in fact GI safer than regular aspirin

FDA Approval

- No aspirin product currently marketed as OTC has FDA NDA approval
- **325 mg** dose approved via 505(b)(2) NDA
- **81 mg** dose sNDA to be filed

Addressing Significant Unmet Need

- **Market research:** Most physicians interviewed have an interest in prescribing or recommending Vazalore for their high-risk patients

Vazalore Market Opportunity: High Risk Patients

Vazalore Initially Targets 4 Sizeable US Patient Populations

	Secondary Prevention Coronary Artery Disease	Secondary Prevention Stroke	Patients with Diabetes > 1 Risk Factor	High Risk Primary Prevention ≥ 2 or more Risk Factors
Addressable Patient Population	~17 million	~8 million	~7 million	~15 million
Total Retail Market Size	\$4.7 billion	\$2.2 billion	\$1.9 billion	\$4.1 billion

1% of this Market = ~\$125 Million Retail Revenue

5% Market Share within 5 years = ~\$625 Million in Retail Revenue

Note: CAD and Stroke assumes a 70% / 30% split between 81 mg and 325 mg while a 80% / 20% split between 81 mg and 325 mg assumed for Diabetes and Primary Prevention.

Specialists & GPs Indicate High Intent to Prescribe Vazalore

Quantitative and Qualitative research positioned Vazalore in the top 5% of all HCP recommended or prescribed products WSM has tested in the past 20+ years (over 200 tests).

	Cardiologists	Neurologists	Endocrinologists Diabetologists	GPs
Number of Physicians:	201	100	100	104
WOULD PRESCRIBE	81%	86%	80%	77%

Weinman Schnee Morais Inc.

Consumers (2,000 surveyed) were more likely to purchase specific OTC products when prescribed by a physician

How Doctors Would Prescribe Vazalore

	Aspirin Therapy Prescribers			
	Cardiologists	Neurologists	Endocrinologists Diabetologists	GPs
Number of Physicians:	201	100	100	104
Patients who have had a cardio-vascular incident/heart attack	83%	78%	87%	83%
Patients who have had a cerebral incident/stroke	71%	88%	72%	76%
Patients with high risk factors	69%	74%	76%	77%
Patients with diabetes	60%	47%	71%	64%
Patients with a family history that puts them at risk	49%	49%	57%	57%
Patients who are overweight/large BMI/obese	33%	35%	34%	39%


¹ Weinman Schnee Morais Inc. (company data)

Brand Strategy


- **Key Drivers**

- Pre-commercial focus on Key Opinion Leaders/Professional Sales & Marketing
- Trade Sales & Marketing
- Consumer/PR

- Drive awareness and trial via physician specialist coverage
- Develop tools to facilitate “pharmacist intervention”
- DTC media follows physician specialist coverage to establish the product



Create Awareness Among HCPs: EC Aspirin's Unsettling Truth



- Condition the market (huge unmet need, patients at risk)
- Engage KOL base about current Aspirin limitations
- Transition awareness to the need for a new standard of care

References: 1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324(7329): 71-86. 2. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. *Am J Med*. 2006;119(8):624-638. 3. FDA. US Code of Federal Regulations Title 21. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=343.80>. Accessed January 29, 2018. 4. Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. *J Am Coll Cardiol*. 2005;47(7):1258-1263. 5. Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. *Stroke*. 2006;37(8): 2153-2158. 6. Kelly JP, Kaufman DW, Jurgelson, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. *Lancet*. 1996;348(9039):1413-1416.

Positioning Vazalore as the New Standard of Care

- **Clinical Data Support:**

- Faster acting than enteric-coated aspirin
- Better antiplatelet efficacy than enteric-coated aspirin
- Better acute GI safety than regular aspirin



Potential to be best-in-class for high-risk CV patients





- **Market Segmentation:**

- Vazalore targets most at risk (secondary prevention)
- PLx intends to evolve the standard of care by leveraging our clinical differentiation across the professional and consumer channels

- **Market research suggests MDs indicate high intent to prescribe**

Pipeline Leverages PLxGuard Platform Technology




















PLxGuard Applicable to a Variety of APIs

Product Candidate	Type	Size	Pre-Clinical	Phase 1	Phase 2	Phase 3
Vazalore Brand Extensions Chronic Pain & Other Vascular Indications*	OTC	48MM High-Risk CVD Patients				
PL1200 Ibuprofen, 200 mg* Pain, Inflammation and Fever	OTC	25.3MM Suffer Daily Chronic Pain ₁				
Other NSAIDs e.g. Indomethacin**, Diclofenac**	OTC & Rx	25.3MM Suffer Daily Chronic Pain ₁				
National Cancer Institute Grant PLx Formula in test with Colorectal Cancer Patients	OTC & Rx	1.3MM Sufferers of Colorectal Cancer ₁				

In clinical (*) and pre-clinical () proof-of-concept studies, these product candidates demonstrated improved GI safety vs. the in-market drug**

1. NIH - National Institutes of Health

PLx Management Team

Name	Experience
Michael (Mike) J. Valentino Executive Chairman of the Board	<ul style="list-style-type: none"> • 35+ years CEO and senior management with successful OTC and Rx brands • OTC brand, Mucinex® (~\$2.3 billion exit in 4.5 years) <div>      </div>
Natasha Giordano President and CEO	<ul style="list-style-type: none"> • 20+ years CEO and senior management commercialization experience <div>       </div>
Rita M. O'Connor Chief Financial Officer	<ul style="list-style-type: none"> • 25+ years pharma and finance leadership at private & public companies <div>    </div>
Steven Valentino VP, Trade Sales	<ul style="list-style-type: none"> • 25+ years in OTC and consumer healthcare including Rx-to-OTC switches, brand management, trade sales <div>    </div>
Mike Dillon VP, Sales & Marketing	<ul style="list-style-type: none"> • Strong track record building high-performing specialty sales teams, launching/promoting blockbuster products <div>   </div>

Independent Board of Directors & Advisors

Director	Experience
Gary S. Balkema	<ul style="list-style-type: none"> Former global head of Bayer Healthcare LLC and Worldwide Consumer Care Division At Bayer USA, repositioned aspirin after ten year decline into a growing business Prior VP and General Manager for American Cyanamid Co.'s Lederle Consumer Health Division
Kirk Calhoun	<ul style="list-style-type: none"> Former audit committee chair, Adams Respiratory Former Partner, Ernst & Young LLP
Robert (Bob) Casale	<ul style="list-style-type: none"> Former Adams Respiratory COO (Mucinex® launch, Adams' IPO and \$2.3 billion sale) Former senior manager at Pfizer, Warner Lambert and CEO of Scerene Healthcare
John W. Hadden II	<ul style="list-style-type: none"> Former CEO of IRX Therapeutics (private) Former healthcare investment banker at JP Morgan & Co.

Scientific Advisory Board



Deepak L. Bhatt, MD
Professor of Medicine
Harvard Medical School
Boston, MA



Dominick Angiolillo, MD
Department of Medicine
Division of Cardiology
University of Florida
Jacksonville, FL



Gabriel Steg, MD
Professor of Cardiology at the Université
Paris - Diderot, Sorbonne-Paris Cité
Université Paris-Diderot, Sorbonne Paris
Cité
Paris, France



Todd Rosengart, MD
Professor and Chair, Department of Surgery
Baylor College of Medicine
Texas Heart Institute, Houston, TX



Byron Cryer, MD
Gastroenterologist
Professor of Medicine
University of Texas
Dallas, TX



Carey Kimmelstiel, MD
Director, Interventional Cardiology
Center; Associate Professor, Tufts
University School of Medicine
Tufts
Boston, MA



Jayne Prats, PhD
Executive Consultant at ELYSIS-Med
Scientific Solutions
Elysis
Boston, MA



Efthymios N. Deliargyris, MD,
PLx Pharma Chief Medical Advisor

Novel Drug Delivery Technology

Achieves greater efficacy with improved acute GI safety

Mechanism of action enables strong patent life and is applicable to a variety of APIs

Lead Product: Vazalore™



Clinically proven to overcome the limitations of enteric-coated aspirin with faster-acting, more reliable and predictable efficacy and improved acute GI Safety




Late-stage product opportunity: Over-the-Counter (OTC), next generation aspirin with a 325mg dose (FDA approved) and an 81mg dose both expected to launch by mid-2020



Addresses a \$12+ billion high-risk cardiovascular patient market



•World-renowned key opinion leader advisory board (including Chairman, Dr. Deepak L. Bhatt and Dr. Gabrielle Steg) that understand and advocate for our innovative solution as a new standard of care



Significant physician interest in Vazalore – WSM¹ research positioned Vazalore in the top 5% of all health care professional recommended or prescribed products tested in the past 20+ years

1- Weinman Schnee Morais Inc.



THANK YOU!